Clincosm LogoSign in Get a demo

A Novel Prognostic Model of NPI for Risk-Predicting and Clinical Decision-making in Diffuse Large B-Cell Lymphoma in the Rituximab Era

Sponsor
Sun Yat-sen University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04624971
Collaborator
(none)
2,000
Enrollment
3
Locations
666.7
Patients Per Site

Study Details

Study Description

Brief Summary

The purpose of this study is to determine the predictive value of a model of Nomogram Prognostic Index (NPI) in patients with Diffuse Large B cell lymphoma.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    2000 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    A Novel Prognostic Model of NPI for Risk-Predicting and Clinical Decision-making in Diffuse Large B-Cell Lymphoma in the Rituximab Era
    Anticipated Study Start Date :
    Nov 1, 2020
    Anticipated Primary Completion Date :
    Nov 1, 2020
    Anticipated Study Completion Date :
    Nov 1, 2020

    Outcome Measures

    Primary Outcome Measures

    1. Overall survival [5-year]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • histologically confirmed diagnosis of CD20+ DLBCL
    Exclusion Criteria:

    • primary central nervous system lymphoma

    • "double-hit" lymphoma

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Guangdong General Hospital Guangzhou Guangdong China 510000
    2 Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou China 51000
    3 Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University, Guangzhou China 51000

    Sponsors and Collaborators

    • Sun Yat-sen University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Qingqing Cai, Chief physician, Sun Yat-sen University
    ClinicalTrials.gov Identifier:
    NCT04624971
    Other Study ID Numbers:
    • B2020-235-01
    First Posted:
    Nov 12, 2020
    Last Update Posted:
    Nov 12, 2020
    Last Verified:
    Nov 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Lymphoma
    Lymphoma, B-Cell
    Lymphoma, Large B-Cell, Diffuse

    Study Results

    No Results Posted as of Nov 12, 2020